DDInter915 DDInter1788
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+).
Indacaterol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Milnacipran
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetryzoline
Indacaterol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetryzoline
Indacaterol {u} (Compound) causes {v} (Side Effect) Malnutrition
Malnutrition {u} (Side Effect) is caused by {v} (Compound) Selegiline
Selegiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Tetryzoline
Indacaterol {u} (Compound) causes {v} (Side Effect) Tachycardia
Tachycardia {u} (Side Effect) is caused by {v} (Compound) Methylergometrine
Methylergometrine {u} may lead to a major life threatening interaction when taken with {v} Tetryzoline
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetryzoline
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetryzoline
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetryzoline
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetryzoline
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Ergometrine
Ergometrine {u} may lead to a major life threatening interaction when taken with {v} Tetryzoline
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Selegiline
Selegiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Tetryzoline
Indacaterol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Milnacipran (Compound) and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Indacaterol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Indacaterol (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Selegiline (Compound) and Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Selegiline may lead to a major life threatening interaction when taken with Tetryzoline
Indacaterol (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Methylergometrine (Compound) and Methylergometrine may lead to a major life threatening interaction when taken with Tetryzoline
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Indacaterol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ergometrine (Compound) and Ergometrine may lead to a major life threatening interaction when taken with Tetryzoline
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Selegiline (Compound) and Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Selegiline may lead to a major life threatening interaction when taken with Tetryzoline